McKinsey Execs On Expanding Pharma’s Digital Push, Lessons From Amazon
Executive Summary
Two McKinsey & Company executives share their views on pharma’s digital trajectory, including the role of manufacturing ‘lighthouses’ and opportunities to deploy digital and analytical tools across the entire value chain for both innovator and generic firms. They see Amazon’s playbook on leveraging digital technology as holding some interesting lessons for pharma.
You may also be interested in...
McKinsey Exec On Pharma's Digital Shift, Deal-Making Expectations
McKinsey India's head of pharmaceutical and healthcare practice shares insights on pharma’s risk management efforts and accelerated deployment of digital technologies, including augmented reality headsets for shop floor operators amid the pandemic. He expects a broad surge in deal-making and says pharma is poised for a “full recovery” soon.
Boehringer India Chief On Putting Pedal To Metal For Digital Engagements
COVID-19 and the related lockdown has sharply curtailed pharma’s face-to-face interactions with healthcare professionals. Boehringer Ingelheim India managing director Sharad Tyagi shares insights on the “extraordinary surge” in the usage of digital platforms during these challenging times. The German multinational has been able to connect with over 30,000 HCPs across the country via digital channels.
Six Questions For McKinsey Executives On Pharma’s Digital Experience
McKinsey & Co executives Vikas Bhadoria and Parag Patel, in an interview with Scrip, shared some key insights into pharma’s recent efforts around digitization and advanced analytics including the emergence of a Bayer site as a manufacturing ‘lighthouse’, Novartis’ Nerve Live platform and sales rep versus digital channel effectiveness.